Trial · NCT00835237
Results by group60
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 60
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Subjects With Antibody Concentration Against Vaccine Antigens, Above a Protocol Defined Cut-off Value | Boostrix Group | Anti-D (≥ 0.1 IU/mL) (N= 859;432) | 729 | subjects | |
| Number of Subjects With Antibody Concentration Against Vaccine Antigens, Above a Protocol Defined Cut-off Value | Decavac Group | Anti-D (≥ 0.1 IU/mL) (N= 859;432) | 374 | subjects | |
| Number of Subjects With Antibody Concentration Against Vaccine Antigens, Above a Protocol Defined Cut-off Value | Boostrix Group | Anti-T (≥ 0.1 IU/mL) (N= 864;439) | 836 | subjects | |
| Number of Subjects With Antibody Concentration Against Vaccine Antigens, Above a Protocol Defined Cut-off Value | Decavac Group | Anti-T (≥ 0.1 IU/mL) (N= 864;439) | 428 | subjects | |
| Number of Subjects With Antibody Concentration Against Vaccine Antigens, Above a Protocol Defined Cut-off Value | Boostrix Group | Anti-T (≥ 1.0 IU/mL) (N= 864;439) | 767 | subjects | |
| Number of Subjects With Antibody Concentration Against Vaccine Antigens, Above a Protocol Defined Cut-off Value | Decavac Group | Anti-T (≥ 1.0 IU/mL) (N= 864;439) | 395 | subjects | |
| Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration | Boostrix Group | Anti-PT (PRE) (N=859;433) | 6.6 | 95% Confidence Interval 6.1 to 7.1 | EL.U/mL |
| Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration | Decavac Group | Anti-PT (PRE) (N=859;433) | 6.5 | 95% Confidence Interval 5.8 to 7.2 | EL.U/mL |
| Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration | Boostrix Group | Anti-PT (POST) (N=852;431) | 49.1 | 95% Confidence Interval 44.9 to 53.7 | EL.U/mL |
| Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration | Decavac Group | Anti-PT (POST) (N=852;431) | 6.4 | 95% Confidence Interval 5.8 to 7.1 | EL.U/mL |
| Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration | Boostrix Group | Anti-FHA (PRE) (N=848;430) | 50.2 | 95% Confidence Interval 46.2 to 54.5 | EL.U/mL |
| Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration | Decavac Group | Anti-FHA (PRE) (N=848;430) | 44.3 | 95% Confidence Interval 39.5 to 49.5 | EL.U/mL |
| Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration | Boostrix Group | Anti-FHA (POST) (N=835;428) | 689.0 | 95% Confidence Interval 638.8 to 743.1 | EL.U/mL |
| Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration | Decavac Group | Anti-FHA (POST) (N=835;428) | 44.4 | 95% Confidence Interval 39.7 to 49.7 | EL.U/mL |
| Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration | Boostrix Group | Anti-PRN (PRE) (N=864;439) | 8.1 | 95% Confidence Interval 7.4 to 8.8 | EL.U/mL |
| Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration | Decavac Group | Anti-PRN (PRE) (N=864;439) | 7.8 | 95% Confidence Interval 6.9 to 8.8 | EL.U/mL |
| Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration | Boostrix Group | Anti-PRN (POST) (N=865;439) | 104.2 | 95% Confidence Interval 91.3 to 118.9 | EL.U/mL |
| Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration | Decavac Group | Anti-PRN (POST) (N=865;439) | 7.7 | 95% Confidence Interval 6.8 to 8.7 | EL.U/mL |
| Anti-T and Anti-D Antibody Concentrations | Boostrix Group | Anti-D (PRE) (N=844;430) | 0.2 | 95% Confidence Interval 0.2 to 0.2 | IU/mL |
| Anti-T and Anti-D Antibody Concentrations | Decavac Group | Anti-D (PRE) (N=844;430) | 0.2 | 95% Confidence Interval 0.1 to 0.2 | IU/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00835237/results